About Us

We believe in this technology and its ability to have a truly positive impact in Oncology.
OncoSil™ For Healthcare Professionals

Our Approvals

We operate from 2 locations globally with access to 11 global markets via direct sales and distributors and operates facilities in Germany.

Global Headquarters

Global Headquarters
OncoSil Medical Ltd.
Level 5, 7 Eden Park Drive
Macquarie Park,
NSW, 2113

European Office

OncoSil Medical Europe GmbH
Kurfuerstendamm 195/3rd Fl.
10707 Berlin

Learn more about our achievements and the people behind them.

Our People
Our History
1. OncoSil™ is intended for intratumoural implantation into a pancreatic tumour via injection under endoscopic ultrasound guidance. OncoSil™ is indicated for the treatment of patients with locally advanced unresectable pancreatic cancer, in combination with gemcitabine based chemotherapy.
2. Skowronek J. J Contemp Brachytherapy 2017; 9: 581-589.
3. PanCO ClinicalTrials.gov Identifier: NCT03003078
4. OncoPaC-1 ClinicalTrials.gov Identifier: NCT03076216
5. PanCO Publication